Conference Reports for NATAP

Back

The International Liver Congress™ EASL 2017 - European Association for the Study of the Liver Amsterdam, The Netherlands. 2017     Summary from EASL 2017 for Hepatitis C - Global implementation of Hepatitis C (HCV) treatment: What are the successes, what are the remaining challenges? - Jurgen K. Rockstroh M.D., Professor of Medicine University of Bonn, Germany - (06/01/17)   Hepatic Fibrosis is Associated With Histological Activity in Non-alcoholic Steatohepatitis: an Analysis From a Large Database of Screening Biopsies in the CENTAUR Trial - (09/08/17)   A NEW NON-INVASIVE DIAGNOSTIC SCORE TO MONITOR CHANGE IN DISEASE ACTIVITY AND PREDICT FIBROSIS EVOLUTION IN PATIENT WITH NASH - (07/17/17)   Prospective Prevalence Study of Adult NAFLD/NASH Utilizing Multi-Modality Imaging Compared with Liver Biopsy - (07/17/17)   Further delineation of fibrosis progression in NAFLD: evidence from a large cohort of patients with sequential biopsies - (07/17/17)   Simple non-invasive fibrosis scores identify patients with NAFLD who progress to advanced fibrosis/cirrhosis: evidence from a large cohort of patients with sequential liver biopsies. - (07/17/17)   DNA Methylation Signatures in Blood Show Accelerated Epigenetic Aging in Patients with Nonalcoholic Steatohepatitis Compared to Healthy Controls - (07/07/17)   Changes in Fibrosis, But Not the NAFLD Activity Score, Are Associated with Disease Progression in Patients with Nonalcoholic Steatohepatitis and Advanced Fibrosis - (07/06/17)   Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial - (07/05/17)   INT 747 (obeticholic acid) fails to achieve goals in Japanese study for non-alcoholic steatohepatitis (NASH)- Intercept Pharma + Sumitomo - (07/05/17)   Starting the battle to control non-alcoholic steatohepatitis [OCA FLINT Study] - Comment - (07/05/17)   Nonalcoholic Steatohepatitis Drug Pipeline Overview - (07/05/17)   Regenerate: a phase 3, double-blind, randomized, placebo-controlled multicenter study of obeticholic acid therapy for nonalcoholic steatohepatitis - (07/05/17)   Elafibranor - (GFT505) NASH Treatment - GOLDEN 505 Study & Commentary - (07/05/17)   Improvement of hepatic fibrosis in patients with non-alcoholic steatohepatitis treated with selonsertib is associated with improvement of patient-reported outcomes - (07/05/17)   Evaluation of Cytochrome P450- and Transporter-Mediated Drug-Drug Interactions With the Farnesoid X Receptor Agonist GS-9674, and Phenotypic Probe Substrates and Inhibitors/Inducers - (07/03/17)   Longitudinal Changes in Liver Stiffness by Magnetic Resonance Elastography, Liver Fibrosis, and Serum Markers of Fibrosis in a Multicenter Clinical Trial in Nonalcoholic Steatohepatitis - (07/03/17)   Emerging Treatments for ASH & NASH - Rohit Loomba, MD / AASLD 2016 - (07/03/17)   A Liver-Targeted Acetyl-CoA Carboxylase Inhibitor Reduces Hepatic Steatosis and Liver Injury in a Murine Model of NASH - (07/03/17)   Hepatic Proton Density Fat Fraction Correlates With Histologic Measures of Steatosis and Is Responsive to Changes in Those Measures in a Multicenter Nonalcoholic Steatohepatitis Clinical Trial - (07/03/17)   Apoptosis Signal-Regulating Kinase 1 Inhibition Reduces Liver Fibrosis and Apoptosis in an NLRP3 Mutant Model of NASH - (07/03/17)   Impact of Weight Reduction on Serum Markers and Liver Histology Including Progression to Cirrhosis in Patients With Nonalcoholic Steatohepatitis and Bridging Fibrosis - (07/03/17)   Impact of Modest Weight Reduction on Liver Histology, Portal Pressure, and Clinical Events in Patients With Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis - (07/03/17)   Longitudinal Changes in Liver Stiffness by Magnetic Resonance Elastography, Liver Fibrosis, and Serum Markers of Fibrosis in a Multicenter Clinical Trial in Nonalcoholic Steatohepatitis - (07/03/17)   Evaluation of the Xpert® HCV Viral Load point-of-care assay from venipuncture-collected and finger-stick capillary whole-blood samples: A prospective study - (06/26/17)   TREATMENT CASCADE OF HEPATITIS B AND C IN GENERAL, MIGRANT AND ROMA POPULATIONS - (06/15/17)   Prevalence and Risk factors of Nonalcoholic Fatty Liver Disease in Metabolically Healthy Obese Adolescents in the United States: An Analysis of National Health and Nutrition Examination Survey Data - (06/07/17)   Trends in hospital charges and encounters for patients with nonalcoholic fatty liver disease compared to patients with alcoholic liver disease in the United States between 2005 and 2013 - (06/07/17)   Multi-Target DAA Therapy is Associated with Superior Immunologic Recovery in HIV/HCV Co-Infected Patients - (06/07/17)   CCR5+ T cells are primary responders to HCV subject to exhaustion and contribute to ongoing hepatic inflammation - (06/07/17)   Incidence and prevalence of recorded non-alcoholic fatty liver disease in four European primary care databases covering 21.9 million adults - (06/02/17)   THE IMPACT OF BROADER HEPATITIS C VIRUS TREATMENT STRATEGIES ON POPULATION HEALTH AND SOCIAL VALUE IN ENGLAND - (06/02/17)   No change in HCV-specific T cell functionality after successful DAA treatment in chronic hepatitis C patients. - (06/02/17)   A pilot study for safety and efficacy of 12 weeks sofosbuvir plus daclatasvir with or without ribavirin in egyptian adolescents with chronic hepatitis C virus Infection - (06/02/17)   Access to hepatitis C treatment in Europe: findings from the 2016 Hep-CORE study - (05/30/17)   High prevalence of chronic hepatitis C in injecting drug users in Tanzania, East Africa: a neglected burden of disease - (05/30/17)   HCC Occurrence or Recurrence After DAA SVR at EASL 2017 - (05/30/17)   Outcomes of Treatment for Hepatitis C Virus Infection in the Prison Setting - (05/30/17)   Projected impact and pathways to success of the hepatitis C virus elimination program in Georgia, 2015-2020 - (05/30/17)   Prevention of Liver-Related Complications With Elbasvir/Grazoprevir in Hepatitis C Infected Patients Who Are Receiving Opioid Agonist Therapy (OAT) - (05/26/17)   Safety and Efficacy of Ombitasvir, Paritaprevir/Ritonavir and Dasabuvir With or Without Ribavirin in Chronic Hepatitis C Patients Receiving Opioid Substitution Therapy: A Pooled Analysis Across 12 Clinical Trials - (05/26/17)   The Novel FXR Agonist, EDP-305, Reduces Fibrosis Progression in Rodent Models of Primary Biliary Cholangitis and Non-alcoholic Steatohepatitis - (05/26/17)   A novel farnesoid X receptor agonist: EDP-305, reduces fibrosis progression in animal models of fibrosis - (05/23/17)   Enanta Announces New Preclinical Data on its FXR Agonist EDP-305 for Non-Alcoholic Steatohepatitis (NASH) and Primary Biliary Cholangitis (PBC) at The International Liver Congress™ 2017 - (05/23/17)   EDP-305, a novel and highly potent farnesoid X receptor agonist, improves liver steatosis, ballooning and non-alcoholic fatty liver disease (NAFLD) activity score (NAS) in a diet-induced murine model of non-alcoholic steatohepatitis - (05/23/17)   Efficacy and Safety of Simtuzumab for the Treatment of NASH with Bridging Fibrosis or Cirrhosis: Results of Two Phase 2b, Dose-Ranging, Randomized, Placebo-Controlled Trials - (05/23/17)   Treatment with Selonsertib, an Inhibitor of Apoptosis Signal-Regulating Kinase 1 (ASK1), Reduces Hepatic Phospho-p38 Expression and Markers of Hepatocellular Apoptosis and Necrosis in Patients with NASH - (05/23/17)   Acetyl-CoA Carboxylase Inhibitor GS-0976 Leads to Suppression of Hepatic De Novo Lipogenesis and Significant Improvements in MRI-PDFF, MRE and Markers of Fibrosis after 12 Weeks of Therapy in Patients with NASH - (05/23/17)   Pharmacokinetics of Selonsertib, GS-9674, and/or GS-0976 in Combination in Healthy Subjects - (05/23/17)   EFFECTIVENESS AND SAFETY OF SOFOSBUVIR/LEDIPASVIR TREATMENT FOR MONOINFECTED GENOTYPE 1 HCV PATIENTS IN REAL-LIFE CLINICAL PRACTICE: RESULTS FROM SPANISH HEPA-C COHORT - (05/23/17)   HBV - Arbutus Announces Corporate Update and First Quarter 2017 Financial Results - (05/09/17)   In Vitro and In Vivo Characterization of the Selective Toll-Like Receptor 8 Agonist GS-9688 - (05/18/17)   Sustained Efficacy and Seroconversion With the Selective Toll-Like Receptor 8 Agonist GS-9688 in the Woodchuck Model of Chronic Hepatitis B - (05/18/17)   In Vivo Pharmacodynamics of GS-5801, a Liver-Targeted Prodrug of a Lysine Demethylase-5 Inhibitor With Antiviral Activity Against Hepatitis B Virus - (05/18/17)   Antiviral Activity of GS-5801, a Liver-Targeted Prodrug of a Lysine Demethylase-5 Inhibitor, in a Hepatitis B Virus Primary Human Hepatocyte Infection Model - (05/18/17)   A Phase 3 Study Comparing Tenofovir Alafenamide to Tenofovir Disoproxil Fumarate in Patients With HBeAg-Positive, Chronic Hepatitis B: Efficacy and Safety Results at Week 96 - (05/15/17)   Restrictions for reimbursement of interferon-free direct acting antiviral therapies for HCV infection in Europe - (05/15/17)   The path towards hepatitis C elimination in Australia following universal access to interferon-free treatments - (05/15/17)   Rising healthcare utilization and cost of chronic hepatitis B: real-world analysis of 44,026 chronic hepatitis B patients and 121,568 matched non-chronic hepatitis B controls in the United States - (05/09/17)   New HCV Drugs at EASL 2017 - (05/09/17)   Treatment as Prevention for Hepatitis C in Iceland (TraP HepC). Real-world experience from a nationwide elimination program using direct acting antiviral agents - (05/09/17)   Comparison of Efficacy and Safety of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir ± Ribavirin Between Asian and Western HCV GT1b-infected Patients - (05/09/17)   Efficacy and Safety of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir in Non-Cirrhotic Asian Patients With Genotype 1b Chronic Hepatitis C Virus Infection: ONYX-I Post-Treatment Week 24 Results - (05/09/17)   Oral Presentation at EASL Highlights ContraVir's Tenofovir Exalidex (TXL™) Antiviral Activity in Hepatitis B (HBV) Patients - (05/05/17)   A Phase 2a Study Evaluating the Multi-dose Activity of ARB-1467 in HBeAg-Positive and -Negative Virally Suppressed Subjects with Hepatitis B - (05/05/17)   Hepatic targeted RNA interference provides deep and prolonged knockdown of alpha-1 antitrypsin levels in ZZ patients - (04/26/17)   In Vitro and In Vivo Characterization of the Selective Toll-Like Receptor 8 Agonist GS-9688 - (05/18/17)   Sustained Efficacy and Seroconversion With the Selective Toll-Like Receptor 8 Agonist GS-9688 in the Woodchuck Model of Chronic Hepatitis B - (05/18/17)   In Vivo Pharmacodynamics of GS-5801, a Liver-Targeted Prodrug of a Lysine Demethylase-5 Inhibitor With Antiviral Activity Against Hepatitis B Virus - (05/18/17)   Antiviral Activity of GS-5801, a Liver-Targeted Prodrug of a Lysine Demethylase-5 Inhibitor, in a Hepatitis B Virus Primary Human Hepatocyte Infection Model - (05/18/17) A Phase 3 Study Comparing Tenofovir Alafenamide to Tenofovir Disoproxil Fumarate in Patients With HBeAg-Positive, Chronic Hepatitis B: Efficacy and Safety Results at Week 96 - (05/16/17)   A Phase 3 Study Comparing Tenofovir Alafenamide to Tenofovir Disoproxil Fumarate in Patients With HBeAg-Positive, Chronic Hepatitis B: Efficacy and Safety Results at Week 96 - (05/15/17)   Arbutus Announces Corporate Update and First Quarter 2017 Financial Results - (05/09/17)   Continued Improvement in Renal Laboratory Parameters in CHB Patients Treated With Tenofovir Alafenamide Compared With Tenofovir Disoproxil Fumarate Over 96 Weeks - (05/05/17) The cyclophilin inhibitor CRV431 prevents both HBx-cyclophilin complex formation and HBV replication - (05/05/17)   Data Enhances Understanding of ContraVir's Complementary Anti-HBV Compounds Tenofovir Exalidex (TXL™) and CRV431 Presentation Elucidating CRV431 Mode of Action Selected for EASL "Poster Tour" - (05/05/17)   CRV431 and CMX157 (TXL; tenofovir exalidex): Anti-HBV combination effects in vitro between a cyclophilin inhibitor and a nucleotide prodrug - (05/05/17)   Oral Presentation at EASL Highlights ContraVir's Tenofovir Exalidex (TXL™) Antiviral Activity in Hepatitis B (HBV) Patients - (05/05/17)   Pharmacokinetics, Safety and Tolerability of Tenofovir exalidex (CMX157), a Novel Prodrug of Tenofovir, Administered as Ascending Multiple Doses to Healthy Volunteers and HBV-Infected Subjects - (05/05/17)   Update on safety and efficacy in the REP 401 protocol: REP 2139-Mg or REP 2165-Mg used in combination with tenofovir disoproxil fumarate and pegylated Interferon alpha-2a in treatment naïve caucasian patients with chronic HBeAg negative HBV infection - (05/05/17)   No changes in the coding sequence for HBV core protein after 6 weeks of treatment of HBV infected humanized mice with NVR 3-778 - (05/05/17)   A Phase 2a Study Evaluating the Multi-dose Activity of ARB-1467 in HBeAg-Positive and -Negative Virally Suppressed Subjects with Hepatitis B - (05/05/17)   Hepatic targeted RNA interference provides deep and prolonged knockdown of alpha-1 antitrypsin levels in ZZ patients - (04/26/17)   A phase 1 study to evaluate safety and tolerability of escalating single doses of the HBV RNA interference drug ARC-521 in a healthy volunteer and HBV patient population - (04/26/17)   Prolonged RNA interference therapy with ARC-520 Injection in treatment naïve, HBeAg positive and negative patients with chronic HBV results in significant reductions of HBs antigen - (04/26/17)   A Phase 1 Study Evaluating Anti-PD-1 Treatment With or Without GS-4774 in HBeAg Negative Chronic Hepatitis B Patients - (04/26/17)   DARING-B: Discontinuation of effective entecavir (ETV) or tenofovir (TDF) therapy in non-cirrhotic HBeAg-negative chronic hepatitis B (CHBe-) patients: a prospective Greek study - (04/26/17)   Improved Bone and Renal Safety of Switching from Tenofovir Disoproxil Fumarate (TDF) to Tenofovir Alafenamide (TAF): Preliminary Results From 2 Phase 3 Studies in HBeAg-positive and HBeAg-negative Patients with Chronic Hepatitis B - (04/26/17)   A Phase 3 Study Comparing Tenofovir Alafenamide (TAF) to Tenofovir Disoproxil Fumarate (TDF) in Patients With HBeAg-Negative, Chronic Hepatitis B (CHB): Efficacy and Safety Results at Week 96 - (04/26/17)   Efficacy and Safety of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir in Non-Cirrhotic Asian Patients With Genotype 1b Chronic Hepatitis C Virus Infection: ONYX-I Post-Treatment Week 24 Results - (05/08/17)   Efficacy and Safety of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir With Ribavirin in Asian Patients With Genotype 1b Chronic Hepatitis C Virus Infection and Compensated Cirrhosis: ONYX-II Post-Treatment Week 24 Results - (05/08/17)   Safety and Efficacy of Ombitasvir, Paritaprevir/Ritonavir and Dasabuvir With or Without Ribavirin in Chronic Hepatitis C Patients Receiving Opioid Substitution Therapy: A Pooled Analysis Across 12 Clinical Trials - (05/08/17)   Changes in Markers of Liver Function in Hepatitis C Virus Genotype 1b Asian Patients With Compensated Cirrhosis Treated With Ombitasvir/Paritaprevir/Ritonavir Plus Dasabuvir With Ribavirin in the ONYX-II Study - (05/08/17)   Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir ± Dasabuvir and ± Ribavirin in Adult Renal or Liver Transplant Recipients With HCV Infection (CORAL-I: Cohorts 3-6) - (05/08/17)   ZIRCON: Pharmacokinetics, Safety, and Efficacy of Ombitasvir/Paritaprevir/Ritonavir ± Dasabuvir ± Ribavirin in Adolescents With Genotype 1 or 4 Hepatitis C Virus Infection - (05/08/17)   The Effect of Ribavirin Dosage on the Kinetics of Viral Load Decline and Drug Exposures in Plasma and Liver With OBV/PTV/r + DSV Treatment in Patients With Chronic Hepatitis C Virus Genotype 1a Infection - (05/08/17)   Continued Improvement in Renal Laboratory Parameters in CHB Patients Treated With Tenofovir Alafenamide Compared With Tenofovir Disoproxil Fumarate Over 96 Weeks - (05/05/17)   The cyclophilin inhibitor CRV431 prevents both HBx-cyclophilin complex formation and HBV replication - (05/05/17)   Data Enhances Understanding of ContraVir's Complementary Anti-HBV Compounds Tenofovir Exalidex (TXL™) and CRV431 Presentation Elucidating CRV431 Mode of Action Selected for EASL "Poster Tour" - (05/05/17)   CRV431 and CMX157 (TXL; tenofovir exalidex): Anti-HBV combination effects in vitro between a cyclophilin inhibitor and a nucleotide prodrug - (05/05/17)   Oral Presentation at EASL Highlights ContraVir's Tenofovir Exalidex (TXL™) Antiviral Activity in Hepatitis B (HBV) Patients - (05/05/17)   Pharmacokinetics, Safety and Tolerability of Tenofovir exalidex (CMX157), a Novel Prodrug of Tenofovir, Administered as Ascending Multiple Doses to Healthy Volunteers and HBV-Infected Subjects - (05/05/17)   Update on safety and efficacy in the REP 401 protocol: REP 2139-Mg or REP 2165-Mg used in combination with tenofovir disoproxil fumarate and pegylated Interferon alpha-2a in treatment naïve caucasian patients with chronic HBeAg negative HBV infection - (05/05/17)   No changes in the coding sequence for HBV core protein after 6 weeks of treatment of HBV infected humanized mice with NVR 3-778 - (05/05/17)   A Phase 2a Study Evaluating the Multi-dose Activity of ARB-1467 in HBeAg-Positive and -Negative Virally Suppressed Subjects with Hepatitis B - (05/05/17)   Effect of hepatitis C treatment with ombitasvir/paritaprevir/ritonavir + dasabuvir regimen on patient's health-related quality of life: Analysis of Phase 3a and Phase 3b clinical trials - (05/03/17)   Patients Above 65 Years of Age Achieved the Same SVR12 as Younger Patients Despite Increased Comorbidities: Findings From a Large Real-World, Multi -Country, Observational Cohort of 12-Week Ombitasvir/Paritaprevir/Ritonavir ± Dasabuvir ± Ribavirin - (05/03/17)   Early versus delayed hepatitis C treatment provides increased health benefits at lower costs: A UK cost-effectiveness analysis of genotypes 1 and 4 treatment-naïve patients - (05/03/17)   The cumulative prevalence and incidence of extra-hepatic manifestations in patients with hepatitis C virus infection: real-world evidence from the United States - (05/03/17)   A budget optimization analysis for the treatment and potential elimination of hepatitis C virus infection in the United States - (05/03/17)   Extra-hepatic manifestations from hepatitis C virus infection related to female infertility and adverse pregnancy outcomes: A real-world observation - (05/03/17)   Impact of Hepatoprotective Medications on the Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir ± Ribavirin in Hepatitis C Virus Genotype 1b-infected Asian Patients With and Without Cirrhosis in the ONYX-I and -II Studies - (05/03/17)   Real-world treatment utilization and results in the renaissance of HCV Care: Analyses of treatment for 8,955 Patients from the TRIO Network - (05/03/17)   Impact of Elbasvir/Grazoprevir (EBR/GZR) on Health-Related Quality of Life (HRQOL) and Fatigue in Patients With Chronic Hepatitis C Virus (HCV) Infection and Inherited Blood Disorders (IBLD): Data From the C-EDGE IBLD Study - (05/03/17)   High Efficacy is Accompanied with Substantial Gains in Patient Reported Outcomes in Cirrhotic Patients with Chronic Hepatitis C Treated with Sofosbuvir, Velpatasvir with or without Voxilaprevir: The Data from POLARIS-1, -2, -3 and -4 - (05/02/17)   Safety and Efficacy of Elbasvir and Grazoprevir with or without Ribavirin for the Treatment of HCV Genotype 1: Results of the HCV-TARGET Study - (05/02/17)   Eight Weeks of Treatment with AbbVie's Investigational, Pan-Genotypic Regimen of Glecaprevir/Pibrentasvir (G/P) Achieved High SVR(12) Rates in Challenging to Treat Genotype 3 Chronic Hepatitis C - (05/02/17)   Efficacy and Safety of Glecaprevir/Pibrentasvir in Japanese Patients With Chronic Genotype 2 Hepatitis C Virus Infection With and Without Cirrhosis - (05/01/17)   CERTAIN-1: Efficacy and Safety of Glecaprevir/Pibrentasvir in Japanese Patients With Chronic Genotype 1 Hepatitis C Virus Infection With and Without Cirrhosis - (05/01/17)   Safety and Efficacy of Sofosbuvir/Velpatasvir for the Treatment of Chronic Hepatitis C in Patients Aged 65 Years or Older: A Retrospective Analysis of Phase 3 Studies - (05/01/17)   Safety and Efficacy of Sofosbuvir and Velpatasvir with or without Ribavirin for the Treatment of HCV Genotype 1-6: Results of the HCV-TARGET Study - (05/01/17)   Safety and Efficacy of Sofosbuvir/Velpatasvir for the Treatment of Chronic Hepatitis C in Patients Aged 65 Years or Older: A Retrospective Analysis of Phase 3 Studies - (05/01/17)   Real-world effectiveness and cost per SVR of Sofosbuvir/Velpatasvir in chronic hepatitis C treatment - (05/01/17)   Real World Effectiveness of Ledipasvir/Sofosbuvir (LDV/SOF) for 8 Weeks in Patients Coinfected With HCV GT 1 and HIV-1 - (05/01/17)   Efficacy and safety of sofosbuvir and daclatasvir for 8 weeks in treatment-naïve non-cirrhotic patients with chronic HCV genotype 3 infection - (05/01/17)   HCV clearance after direct-acting antivirals in cirrhotic [advanced] patients by stages of liver impairment: the ITAL-C network study - (05/01/17)   Real-world utilization of the new fixed-dose combination elbasvir/grazoprevir in adult patients with chronic hepatitis C in Canada: Z-PROFILE study - (04/28/17)   High Sustained Virologic Response Rates at 24 Weeks in Participants With Chronic HCV GT1, 2, or 3 Infection Following 16 Weeks of Grazoprevir/Ruzasvir/Uprifosbuvir (MK-3682) Plus Ribavirin After Having Failed 8 Weeks of a Triple Drug Regimen (Part C of C-CREST-1 & 2) - (04/28/17)   HIGH SUSTAINED VIROLOGICAL RESPONSE RATES IN GENOTYPES 1a AND 4 HEPATITIS C PATIENTS TREATED WITH ELBASVIR AND GRAZOPREVIR AND BASAL VIREMIA >800.000 UI/ML - (04/28/17)   Potential effect of hepatitis C treatment on renal, cardiovascular and metabolic extrahepatic manifestations: Results from clinical trials of ombitasvir/paritaprevir/ritonavir and dasabuvir ± ribavirin - (04/28/17)   Does Sofosbuvir (SOF)/Velpatasvir (VEL) with or without Ribavirin (RBV) change the landscape of therapy in chronic hepatitis C genotype 3 (GT 3) infection? - Results from the GErman hepatitis C COhort (GECCO) - (04/28/17)   No increase in the occurrence rate of HCC in Chinese treated by DAAs compared to PR after eradication of HCV: a long-term follow-up - (04/28/17)   Efficacy and Safety of Elbasvir/Grazoprevir in Treatment-Naive Participants With Chronic Hepatitis C Virus Genotype 1, 4, or 6 Infection (C-CORAL): A Phase 3 Randomized, International Trial - (04/28/17)   Real-world effectiveness and cost per SVR of Sofosbuvir/Velpatasvir in chronic hepatitis C treatment / GT3 - (04/26/17)   Direct-acting Antivirals for Hepatitis C Do Not Increase the Risk of Hepatocellular Carcinoma Recurrence After Locoregional Therapy or Liver Transplant Waitlist Dropout - (04/26/17)   Occurrence and Recurrence of Malignancies Post DAA Treatment in 5.1% of Patients- Single Center Experience - (04/26/17)   Degree of Liver Fibrosis Regression Predicted by Transient Elastography after Cure of Chronic Hepatitis C with Direct Acting Antivirals is Overestimated but Confirmed by Liver Biopsy - (04/26/17)   Long-term follow-up after IFN-free therapy of advanced HCV-associated liver cirrhosis: Continued improvement of liver function parameters Results from the German Hepatitis C-Registry (DHC-R) - (04/26/17)   No evidence for higher risk of hepatocellular carcinoma occurrence or recurrence following direct-acting antiviral HCV therapy: A systematic review, meta-analyses, and meta-regression - (04/26/17)   Liver Cancer Emergence Associated with Antiviral Treatment: An Immune Surveillance Failure? - (04/26/17)   THERAPY WITH DIRECT ANTIVIRAL AGENTS IN PATIENTS WITH HCV-RELATED LYMPHOPROLIFERATIVE DISORDERS AND MIXED CRYOGLOBULINEMIA - (04/26/17)   Prognostic value of viral eradication for major adverse cardiovascular events in hepatitis C cirrhotic patients. ANRS CO12 CirVir Cohort - (04/26/17)   Incidence of and predictors for direct acting antiviral treatment failure among 4099 hepatitis C genotype 1 infected adults: Real world outcomes from HCV TARGET - (04/26/17)   Elbasvir/Grazoprevir effectiveness in patients with Chronic Hepatitis C and Chronic Kidney Disease: Real-world experience from the TRIO Network - (04/26/17)   The Safety and Tolerability of SOF/VEL/VOX for 8 or 12 Weeks in >1000 Patients Treated in the POLARIS-1, POLARIS-2, POLARIS-3, and POLARIS-4 Studies: an Integrated Analysis - (04/26/17)   Real-world use of elbasvir/grazoprevir and outcomes in patients with Chronic Hepatitis C: Retrospective data analyses from the TRIO Network. - (04/26/17)   Utilization of DAA therapies ledipasvir/sofosbuvir and sofosbuvir/velpatasvir in patients with genotype 1 HCV: Real-world experience from the TRIO Network. - (04/26/17)   EASL-ILC 2017: Viral Hepatitis - (04/26/17)   Among Cirrhotic Patients with a Hepatitis C Sustained Viral Response, the Risk of De-novo Hepatocellular Carcinoma Relates to Baseline Factors and Not the Use of Direct Acting Antivirals: Results from a Nationwide Cohort - (04/26/17)   Among Cirrhotic Patients with a Hepatitis C Sustained Viral Response, the Risk of De-novo Hepatocellular Carcinoma Relates to Baseline Factors and Not the Use of Direct Acting Antivirals: Results from a Nationwide Cohort - (04/26/17)   IFN-free cure of HCV infection alters the soluble inflammatory milieu in patients with liver cirrhosis which could affect HCC surveillance by CD8+ T cells - (04/26/17)   No Impact of RASs on the High Efficacy of SOF/VEL/VOX for 12 Weeks in DAA-Experienced Patients: an Integrated Resistance Analysis of the POLARIS-1 and POLARIS-4 Studies - (04/26/17)   EASL-ILC 2017: Viral Hepatitis Debrief, Heiner Wedemeyer - (04/26/17)   A Phase 1 Study Evaluating Anti-PD-1 Treatment With or Without GS-4774 in HBeAg Negative Chronic Hepatitis B Patients - (04/26/17)   The PREVAIL Study: Intensive Models of HCV Care for People Who Inject Drugs - (04/26/17)   Four weeks of Ledipasvir/Sofosbuvir + Ribavirin with or without interferon give very high and sustained cure rates in difficult to reach but easy to treat injecting drug users with chronic hepatitis C. Final results of the 4WIDUC study. - (04/26/17)   The Safety and Tolerability of SOF/VEL/VOX for 8 or 12 Weeks in >1000 Patients Treated in the POLARIS-1, POLARIS-2, POLARIS-3, and POLARIS-4 Studies: an Integrated Analysis - (04/26/17)   Hepatic targeted RNA interference provides deep and prolonged knockdown of alpha-1 antitrypsin levels in ZZ patients - (04/26/17)   A phase 1 study to evaluate safety and tolerability of escalating single doses of the HBV RNA interference drug ARC-521 in a healthy volunteer and HBV patient population - (04/26/17)   Prolonged RNA interference therapy with ARC-520 Injection in treatment naïve, HBeAg positive and negative patients with chronic HBV results in significant reductions of HBs antigen - (04/26/17)   A Phase 1 Study Evaluating Anti-PD-1 Treatment With or Without GS-4774 in HBeAg Negative Chronic Hepatitis B Patients - (04/26/17)   DARING-B: Discontinuation of effective entecavir (ETV) or tenofovir (TDF) therapy in non-cirrhotic HBeAg-negative chronic hepatitis B (CHBe-) patients: a prospective Greek study - (04/26/17)   Improved Bone and Renal Safety of Switching from Tenofovir Disoproxil Fumarate (TDF) to Tenofovir Alafenamide (TAF): Preliminary Results From 2 Phase 3 Studies in HBeAg-positive and HBeAg-negative Patients with Chronic Hepatitis B - (04/26/17)   A Phase 3 Study Comparing Tenofovir Alafenamide (TAF) to Tenofovir Disoproxil Fumarate (TDF) in Patients With HBeAg-Negative, Chronic Hepatitis B (CHB): Efficacy and Safety Results at Week 96 - (04/26/17)   Delisting of liver transplant candidates with chronic HCV infection after viral eradication and outcome after delisting. A European cohort study - (04/25/17)   Modelling the Impact of Targeted Interventions on the HCV Epidemic in Pakistan The Road to HCV Elimination - (04/25/17)   CHRONIC HEPATITIS C IN CHILDREN IN THE RUSSIAN FEDERATION: A MULTICENTER STUDY - (04/25/17)   SOF/VEL/VOX Results in High SVR12 Rates When Administered for 12 Weeks in DAA-Experienced Patients or for 8 Weeks in DAA-Naïve Patients: an Integrated Analysis of the POLARIS-1, POLARIS-2, POLARIS-3, and POLARIS-4 Studies - (04/25/17)   High SVR Rates With Eight and Twelve Weeks of Pangenotypic Glecaprevir/Pibrentasvir: Integrated Efficacy Analysis of Genotype 1-6 Patients Without Cirrhosis - (04/25/17)   Elbasvir/Grazoprevir effectiveness in patients with Chronic Hepatitis C and Chronic Kidney Disease: Real-world experience from the TRIO Network - (04/25/17)   Safety and Efficacy of Glecaprevir/Pibrentasvir in Adults With Chronic Hepati is C Virus Infection Genotype 1-6 as a Function of Chronic Kidney Disease Stage - (04/25/17)   Serum Cholesterol Changes Associated with NGM282 Treatment in Obese Insulin Resistant Cynomolgus Monkeys and NASH Patients are Reversed with Lipid Lowering Agents - (04/24/17)   NGM282, a Novel Variant of FGF19, Significantly Reduces Hepatic Steatosis and Key Biomarkers of NASH: Results of a Phase 2, Multicenter, Randomized, Double-Blinded, Placebo Controlled Trial in Biopsy-Confirmed NASH Patients - (04/24/17)   BMS-986036 (pegylated FGF21) in patients with non-alcoholic steatohepatitis: A phase 2 study - (04/24/17)   MAGELLAN-2: SAFETY AND EFFICACY OF GLECAPREVIR/PIBRENTASVIR IN LIVER OR RENAL TRANSPLANT ADULTS WITH CHRONIC HEPATITIS C GENOTYPE 1-6 INFECTION - (04/24/17)   SOF/VEL/VOX for 8 or 12 Weeks Is Well Tolerated and Results in High SVR12 Rates in Patients Receiving Opioid Substitution Therapy - (04/24/17)   Efficacy and safety of sofosbuvir/velpatasvir in people with chronic hepatitis C virus infection and recent injecting drug use: The SIMPLIFY study - (04/24/17)   Early occurrence of hepatocellular carcinoma in patients with HCV cirrhosis treated with direct acting antivirals - (04/24/17)   Safety and Efficacy of the Fixed-dose Combination Regimen of Uprifosbuvir (MK-3682) / Grazoprevir / Ruzasvir in Cirrhotic or Non-cirrhotic Patients with Chronic HCV GT1 Infection Who Previously Failed a Direct-acting Antiviral Regimen (C-SURGE) - (04/24/17)   MAGELLAN-1, PART 2: GLECAPREVIR/PIBRENTASVIR FOR 12 OR 16 WEEKS IN PATIENTS WITH CHRONIC HCV GENOTYPE 1 OR 4 AND PRIOR DIRECT-ACTING ANTIVIRAL TREATMENT FAILURE - (04/24/17)   Short Duration Treatment with AL-335 and Odalasvir, with or without Simeprevir, in Treatment Naïve Patients with Hepatitis C Infection with or without Cirrhosis - (04/24/17)   Ledipasvir/Sofosbuvir for 12 Weeks Is Safe and Effective in Patients with Chronic Hepatitis C and Hepatitis B Coinfection: A Phase 3 Study in Taiwan - (04/24/17)   Sofosbuvir/velpatasvir compared to existing Standards of Care in GT2-6 HCV Real-world experience from the TRIO Network - (04/24/17)   Ledipasvir/Sofosbuvir ± Ribavirin for 12 or 24 Weeks Is Safe and Effective in Children 6-11 years old with Chronic Hepatitis C Infection - (04/24/17)   Gilead Announces Scientific Presentations Demonstrating Efficacy of Harvoni® (Ledipasvir/Sofosbuvir) in Special Patient Populations With HCV Infection - (04/24/17)   Real-World Observational Study in the U.S. Veterans Affairs System Evaluating Use of Merck's ZEPATIER® (Elbasvir and Grazoprevir) Shows High Sustained Virologic Response Rates in Patients with Chronic Hepatitis C - (04/24/17)   Real-World Observational Study in the U.S. Veterans Affairs System Evaluating Use of Merck's ZEPATIER® (Elbasvir and Grazoprevir) Shows High Sustained Virologic Response Rates in Patients with Chronic Hepatitis C - (04/24/17)   Safety of Glecaprevir/Pibrentasvir in Adults With Chronic Genotype 1-6 Hepatitis C Virus Infection: An Integrated Analysis - (04/24/17)   Pooled Resistance Analysis in HCV Genotype 1-6 Infected Patients Treated With Glecaprevir/Pibrentasvir in Phase 2 and 3 Clinical Trials - (04/24/17)   Unexpected high rate of early tumor recurrence in patients with HCV-related HCC undergoing interferon-free therapy - (04/24/17)   Elbasvir/Grazoprevir Plus Sofosbuvir ± Ribavirin in Treatment-Naive And Treatment-Experienced People With Hepatitis C Virus Genotype 3 Infection and Compensated Cirrhosis: SVR24 Results of the C-ISLE Study - (04/21/17)   Among Cirrhotic Patients with a Hepatitis C Sustained Viral Response, the Risk of De-novo Hepatocellular Carcinoma Relates to Baseline Factors and Not the Use of Direct Acting Antivirals: Results from a Nationwide Cohort - (04/21/17)   Nivolumab in Sorafenib-Experienced Patients With Advanced Hepatocellular Carcinoma With or Without Chronic Viral Hepatitis: CheckMate 040 Study - (04/21/17)   ENDURANCE-3: SAFETY AND EFFICACY OF GLECAPREVIR/PIBRENTASVIR COMPARED TO SOFOSBUVIR PLUS DACLATASVIR IN TREATMENT-NAÏVE HCV GENOTYPE 3-INFECTED PATIENTS WITHOUT CIRRHOSIS - (04/21/17)   EXPEDITION-I: Efficacy and Safety of Glecaprevir/Pibrentasvir for Treatment of Chronic Hepatitis C Virus Genotype 1, 2, 4, 5 or 6 Infection in Adults with Compensated Cirrhosis - (04/21/17)   Pharmacokinetics and Safety of Glecaprevir/Pibrentasvir in Adults With Chronic Genotype 1-6 Hepatitis C Virus Infection and Compensated Cirrhosis: An Integrated Analysis - (04/21/17)   A Phase 3 Study Comparing Tenofovir Alafenamide to Tenofovir Disoproxil Fumarate in Patients With HBeAg-Positive, Chronic Hepatitis B: Efficacy and Safety Results at Week 96 - (04/21/17)   EASL Launches Major New Funding Initiative: HCV education/public awareness/elimination - (04/21/17)   Treatment With SOF/VEL or SOF/VEL/VOX Is Well Tolerated and Results in High SVR12 in Genotype 1-6 HCV-Infected Patients With Minimal Fibrosis: a Retrospective Analysis of the ASTRAL and POLARIS Clinical Studies - (04/21/17)   High Sustained Virologic Response Rates at 24 Weeks in Participants With Chronic HCV GT1, 2, or 3 Infection Following 16 Weeks of Grazoprevir/Ruzasvir/Uprifosbuvir (MK-3682) Plus Ribavirin After Having Failed 8 Weeks of a Triple Drug Regimen (Part C of C-CREST-1 & 2) - (04/20/17)   Efficacy and Safety of the Fixed-Dose Combination Regimen of Grazoprevir/Ruzasvir/Uprifosbuvir (MK-3682) With or Without Ribavirin in Non-cirrhotic or Cirrhotic Participants With Chronic HCV GT1, 2, 3, 4, or 6 Infection (Parts A & B of C-CREST-1 & 2) - (04/20/17)   Efficacy and Safety of Glecaprevir/Pibrentasvir in Patients Co-infected With Hepatitis C Virus and Human Immunodeficiency Virus-1: The EXPEDITION-2 Study - (04/20/17)   No Impact of RASs on the High Efficacy of SOF/VEL/VOX for 8 Weeks in DAA-Naïve Patients: an Integrated Resistance Analysis of the POLARIS-2 and POLARIS-3 Studies - (04/20/17)   ILC 2017: Is direct-acting antiviral therapy for Hepatitis C associated with an increased risk of liver cancer? The debate continues - (04/20/17)   Arrowhead Pharmaceuticals Announces Presentations at The International Liver Congress™ - (04/20/17)   Merck to Present New Data on ZEPATIER® (elbasvir and grazoprevir) and Investigational Combination Therapy MK-3682B for the Treatment of Chronic Hepatitis C Infection at The International Liver Congress™ 2017 - (04/07/17)